Tirzepatide vs SGLT2 Inhibitors in MASLD Across Disease Stages

A study presented at The Liver Meeting 2026 suggests that tirzepatide is more effective than SGLT2 inhibitors in reducing major adverse liver and cardiovascular outcomes in patients with type 2 diabetes and MASLD. The findings indicate benefits across both noncirrhotic and compensated cirrhosis patient groups.
Why it matters
This research provides critical real-world evidence for clinicians managing metabolic liver disease in diabetic patients, potentially shifting standard treatment protocols.
Among adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD), starting tirzepatide was associated with fewer major adverse liver outcomes (MALO) and cardiovascular events than starting a sodium-glucose cotransporter 2 (SGLT2) inhibitor, according to research presented by Mohammad Alabbas, MD, at The Liver Meeting 2026 in Denver, Colorado.
Alabbas, a research fellow in the hepatology section of the Department of Gastroenterology at Cleveland Clinic, told HCP Live that type 2 diabetes is a key risk factor for MASLD and that both drug classes are widely used in this population. Patients with compensated cirrhosis, however, are underrepresented in clinical trials, and clinicians sometimes prescribe these agents off label for them.
How Did Outcomes Differ by Disease Stage?
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in